Alnylam announces retirement of longtime board member, dr. phillip a. sharp, company co-founder and industry luminary

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced the retirement of dr. phillip a. sharp, ph.d., from the company's board of directors, effective as of may 8, 2025. dr. sharp has served as a key advisor to alnylam since he co-founded the company in 2002. dr. sharp will remain a member of the alnylam scientific advisory board. “phil helped pioneer the rnai revolution, sparking the scientific collaboration that.
ALNY Ratings Summary
ALNY Quant Ranking